Efficacy results will be summarized for the overall treatment regimen. Overall safety will be assessed by descriptive analyses using tabulated frequencies of AEs by grade using CTCAE version 4.03 in terms of treatment- emergent AEs, SAEs, and clinically significant changes in safety laboratory tests, physical examinations, ECGs, ECHOs, and vital signs. ORR will be evaluated in accordance with RECIST Version 1.1 and irRC. The percentage of subjects (and 95% confidence interval [CI]) who achieve a confirmed response will be summarized. DCR will be evaluated similar to ORR. PFS, OS, and DOR will be analyzed using Kaplan- Meier methods. Descriptive statistics of PROs will be presented. Correlations of tumor molecular profiles, therapy-induced changes in immune responses, and molecular changes in ctDNA and ctRNA with subject outcomes will be explored. Confidential and Proprietary 19 NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Figure 1: Study Treatment Schema Confidential and Proprietary 20 NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Figure 2: Induction Phase Treatment Schema Confidential and Proprietary 21 NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Figure 3: Maintenance Phase Treatment Schema Confidential and Proprietary 22 NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 1 Confidential and Proprietary 1 TITLE PAGE NANT TRIPLE NEGATIVE BREAST CANCER (TNBC) VACCINE: MOLECULARLY INFORMED INTEGRATED IMMUNOTHERAPY COMBINING INNATE HIGH -AFFINITY NATURAL KIL LER (ha NK) CELL THERAPY WITH ADENOVIRAL AND YEAST - BASED VACCINES TO INDUCE T -CELL RESPONSES IN SUBJECTS WITH TNBC WHO HAVE PROGRESSED ON OR AFTER STANDARD -OF-CARE THERAPY Study Number: QUILT -3.067 IND Sponsor: NantKwest, Inc. 9920 Jefferson Blvd Culver City, CA 90232 Sponsor Contact: (For medical questions/emergencies) John H.